Original Paper

You have free access to this content

Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males

  1. Nancy Hakooz1,*,
  2. Isam I. Salem2

Article first published online: 5 FEB 2012

DOI: 10.1002/bdd.1770

Issue

Biopharmaceutics & Drug Disposition

Biopharmaceutics & Drug Disposition

Volume 33, Issue 1, pages 15–21, January 2012

Additional Information

How to Cite

Hakooz, N. and Salem, I. I. (2012), Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males. Biopharm. Drug Dispos., 33: 15–21. doi: 10.1002/bdd.1770

Author Information

  1. 1

    Faculty of Pharmacy, University of Jordan, Amman, Jordan

  2. 2

    IPRC International Pharmaceutical Research Center, Sport City Circle

*Faculty of Pharmacy, Zarqa University, Zarqa 13132, Jordan.
E-mail: nhakooz@ju.edu.jo

Publication History

  1. Issue published online: 7 MAR 2012
  2. Article first published online: 5 FEB 2012
  3. Accepted manuscript online: 23 JAN 2012 06:20AM EST
  4. Manuscript Accepted: 7 JAN 2012
  5. Manuscript Revised: 28 DEC 2011
  6. Manuscript Received: 1 NOV 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (142K)

References

  • 1
    Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001; 107: 751–762.
  • 2
    Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol 2002; 449: 229–237.
  • 3
    Bachert C, Maurer M. Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig 2010; 30: 109–122.
  • 4
    Ortonne JP. Urticaria and its subtypes: The role of second-generation antihistamines. Eur J Intern Med 2012; 23: 26–30.
  • 5
    Gupta S, Banfield C, Affrime M, et al. Desloratadine demonstrates dose proportionality in healthy adults after single doses. Clin Pharmacokinet 2002; 41 (Suppl 1): 1–6.
  • 6
    Ramanathan R, Reyderman L, Su AD, et al. Disposition of desloratadine in healthy volunteers. Xenobiotica 2007; 37: 770–787.
  • 7
    Prenner B, Kim K, Gupta S, et al. Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. Expert Opin Drug Saf 2006; 5: 211–223.
  • 8
    Affrime M, Banfield C, Gupta S, et al. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clin Pharmacokinet 2002; 41 (Suppl 1): 21–28.
  • 9
    Gupta S, Banfield C, Affrime M, Marbury T, Padhi D, Glue P. Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet 2002; 41(Suppl 1): 7–12.
  • 10
    DuBuske L. Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol 2007; 8: 271–283.
  • 11
    Banfield C, Herron J, Keung A, Padhi D, Affrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 2002; 41(Suppl 1): 37–44.
  • 12
    Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002; 41: 311–318.
  • 13
    Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002; 41(Suppl 1): 29–35.
  • 14
    Ghosal A, Yuan Y, Hapangama N, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Biopharm Drug Dispos 2004; 25: 243–252.
    Direct Link:
  • 15
    Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004; 18: 399–411.
    Direct Link:
  • 16
    Barecki ME, Casciano CN, Johnson WW, Clement RP. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos 2001; 29: 1173–1175.
  • 17
    Sanchez-Velasco P, Karadsheh NS, Garcia-Martin A, Ruiz de Alegria C, Leyva-Cobian F. Molecular analysis of HLA allelic frequencies and haplotypes in Jordanians and comparison with other related populations. Hum Immunol 2001; 62: 901–909.
  • 18
    Guidance For Industry: Bioanalytical Method Validation for Human Studies. FDA: USA, 2001.
  • 19
    Affrime M, Gupta S, Banfield C, Cohen A. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 2002; 41(Suppl 1): 13–19.
  • 20
    Berger WE. The safety and efficacy of desloratadine for the management of allergic disease. Drug Saf 2005; 28: 1101–1118.
View Full Article (HTML) Get PDF (142K)